In a comparative analysis conducted by Sellebjerg et al., they reported a notable contrast in the proportion of CD4+CD25-high T cells expressing CTLA-4 in untreated MS patients compared with healthy controls [36]. This evidence concerns the gene CD4 and myeloid sarcoma.